stars 1 stars 2 stars 3

Heragen, Inc. is developing a novel genomic based Breast Cancer Recurrence Test. Heragen, Inc. will help physicians and oncologists make educated decisions using a patented technology. Heragen, Inc. is a spin-off from the Breast Cancer Startup Challenge conducted by National Institute of Health (NIH), National Cancer Institute (NCI), Avon Foundation and Center for Advanced Innovation (CAI).

Heragen Questions

The NAICS codes for Heragen are [541, 5417, 541711, 54171, 54].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users